🎉 M&A multiples are live!
Check it out!

Mural Oncology Valuation Multiples

Discover revenue and EBITDA valuation multiples for Mural Oncology and similar public comparables like Benevolent AI, Julphar, and Pharming.

Mural Oncology Overview

About Mural Oncology

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.


Founded

2017

HQ

United States of America
Employees

116

Financials

LTM Revenue $2.3M

LTM EBITDA -$117M

EV

-$119M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Mural Oncology Financials

Mural Oncology has a last 12-month revenue of $2.3M and a last 12-month EBITDA of -$117M.

In the most recent fiscal year, Mural Oncology achieved revenue of n/a and an EBITDA of -$135M.

Mural Oncology expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Mural Oncology valuation multiples based on analyst estimates

Mural Oncology P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$194M -$135M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$200M -$207M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Mural Oncology Stock Performance

As of April 15, 2025, Mural Oncology's stock price is $1.

Mural Oncology has current market cap of $17.7M, and EV of -$119M.

See Mural Oncology trading valuation data

Mural Oncology Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$119M $17.7M XXX XXX XXX XXX $-6.79

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Mural Oncology Valuation Multiples

As of April 15, 2025, Mural Oncology has market cap of $17.7M and EV of -$119M.

Mural Oncology's trades at -51.5x LTM EV/Revenue multiple, and 1.0x LTM EBITDA.

Analysts estimate Mural Oncology's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Mural Oncology and 10K+ public comps

Mural Oncology Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$119M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA 0.9x XXX XXX XXX
P/E -0.1x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 0.9x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Mural Oncology Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Mural Oncology Valuation Multiples

Mural Oncology's NTM/LTM revenue growth is 178%

Mural Oncology's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.2M for the same period.

Over next 12 months, Mural Oncology's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Mural Oncology's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Mural Oncology and other 10K+ public comps

Mural Oncology Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -30% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $1.2M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Mural Oncology Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Mural Oncology M&A and Investment Activity

Mural Oncology acquired  XXX companies to date.

Last acquisition by Mural Oncology was  XXXXXXXX, XXXXX XXXXX XXXXXX . Mural Oncology acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Mural Oncology

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Mural Oncology

When was Mural Oncology founded? Mural Oncology was founded in 2017.
Where is Mural Oncology headquartered? Mural Oncology is headquartered in United States of America.
How many employees does Mural Oncology have? As of today, Mural Oncology has 116 employees.
Who is the CEO of Mural Oncology? Mural Oncology's CEO is Dr. Caroline Loew, PhD.
Is Mural Oncology publicy listed? Yes, Mural Oncology is a public company listed on NAS.
What is the stock symbol of Mural Oncology? Mural Oncology trades under MURA ticker.
When did Mural Oncology go public? Mural Oncology went public in 2023.
Who are competitors of Mural Oncology? Similar companies to Mural Oncology include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Mural Oncology? Mural Oncology's current market cap is $17.7M
What is the current revenue of Mural Oncology? Mural Oncology's last 12-month revenue is $2.3M.
What is the current EBITDA of Mural Oncology? Mural Oncology's last 12-month EBITDA is -$117M.
What is the current EV/Revenue multiple of Mural Oncology? Current revenue multiple of Mural Oncology is -51.5x.
What is the current EV/EBITDA multiple of Mural Oncology? Current EBITDA multiple of Mural Oncology is 1.0x.
Is Mural Oncology profitable? Yes, Mural Oncology is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.